Key takeaways
- Public milestones can show changing work or resources; they do not prove that a purchase, shortlist, or RFP exists.
- There is no defensible universal interval between a public signal and procurement. Internal sourcing may be informal, competitive, incumbent-led, delayed, or absent.
- Manufacturing process design and qualification begin before commercial distribution, so approval is not the moment commercial manufacturing work first appears.
- Funding enables a plan only when disclosed use of proceeds supports it; pair financing with program-specific evidence and keep the conclusion provisional.
Biotech outsourcing does not follow one public timetable. Clinical, financing, regulatory, leadership, and manufacturing events can change the work an account must plan, but none proves that the company is choosing a partner. The defensible use of these events is to identify what to verify next.
Which events justify closer research?
Public events can show new work, resources, or regulatory obligations. They cannot show the internal sourcing choice unless the company discloses it. Four useful research prompts are:
A new study or later-stage program can change clinical, material, and quality requirements. Verify phase and timing, then investigate whether the work is internal, incumbent-supported, or newly sourced.
A funding round, grant, or milestone payment changes resources. Read the stated use of proceeds; it does not by itself show budget allocation or make an external purchase likely.
An IND, expedited-program designation, application filing, or approval can change regulatory work. These events have different meanings, and commercial process design and qualification must be addressed before distribution rather than beginning only after approval.
A new development, CMC, manufacturing, or quality leader indicates organizational change. The person may review vendors, preserve current arrangements, or focus elsewhere; confirm the remit before inferring a buying process.
These map onto the same readiness cues that drive outreach timing more generally. See timing outreach with readiness signals for how new budget, a new need, and new decision-makers each point at a different kind of change inside an account.
When does a company buy CRO services specifically?
Trial design and execution create work in protocol development, operations, data, safety, sites, and monitoring. A sponsor may perform that work internally or transfer documented activities to a service provider while retaining ultimate responsibility for the trial. Clinical activity therefore identifies work to understand, not a guaranteed CRO purchase. The GTM playbook for CROs works through which clinical and hiring events carry the most weight for a CRO specifically.
Clinical operations and development are reasonable functions to research, while the size and complexity of the trial shape service fit. Verify responsibility and authority at the account rather than assigning the purchase from a title or phase.
When does a company buy CDMO services specifically?
Manufacturing planning spans process design, scale-up, qualification, quality oversight, and continued verification. FDA guidance makes clear that these are lifecycle activities. A phase-labeled study or expedited-program designation may justify checking the plan, but it does not reveal capacity, tech-transfer timing, or whether an external facility will be used. The GTM playbook for CDMOs covers why modality functions almost like a hard gate here, and which facility and regulatory events matter most.
Approval is not the point at which commercial manufacturing first becomes necessary. The commercial process and its qualification must be addressed before product is distributed; after approval, routine supply, continued verification, and controlled changes continue. If you are not sure how the roles differ, the CRO vs. CDMO vs. CMO explainer sets out what each actually does.
What usually happens before the RFP goes out?
There is no universal public sequence. A company may define requirements, consult existing partners, qualify facilities, run a competitive process, or keep the work internal. A public RFP proves that a formal process exists at that point; the absence of one says little about whether internal work or supplier discussions have started.
Do not publish a weeks-to-months estimate or claim that a shortlist is already forming without account-specific evidence. Use an upstream event to ask a relevant question and verify whether there is work, fit, and a process.
How long are the lead times, really?
Lead times vary by service scope, modality, protocol, process maturity, facility, geography, quality work, and available capacity. Public milestones do not support a universal number or an urgency label. The useful conclusion is narrower: understand the workstream early enough to ask an informed question, then let account-specific evidence set the timing.
Putting it together: buy triggers by stage
A rough, hedged map of where the common purchases cluster:
- Preclinical into first-in-human. Clinical services and early process development needs form. Investigate which capabilities are internal and which, if any, are transferred to service providers.
- Phase 1 into Phase 2. Trials grow and get more complex; clinical capacity needs expand, and manufacturing scale-up starts to come into view.
- Phase 2 into Phase 3. Study size, evidence, material, and operational requirements may change. Verify the actual protocol and manufacturing plan rather than assuming an outside CDMO evaluation.
- Approaching and reaching approval. Commercial process qualification, launch readiness, quality oversight, supply, continued verification, and change control matter across the boundary; they do not first appear after approval.
- Any stage, after a financing or leadership change. These events can change resources or ownership. Confirm use of proceeds and the leader's remit before inferring a vendor decision.
None of these is a guarantee, and the timing shifts with modality and company size. Treat the map as where to look first, then confirm the specific account against its own recent activity rather than assuming the stage alone settles it.
Primary sources
- ICH E6(R3) Good Clinical Practice explains that transferred trial activities should be documented and that ultimate responsibility remains with the sponsor.
- FDA process validation guidance places commercial process design, qualification, and verification across the lifecycle, including work before commercial distribution.
- FDA contract manufacturing quality-agreement guidance describes documented owner and contract-facility responsibilities.